The future of cancer care: health system sustainability in The Middle East and North Africa (MENA)

United Arab Emirates (UAE)

Supported by





Key trends

As the economy and population of the UAE grow, the number of cancer patients will also significantly increase.

The percentage of the population aged over-65, a high-risk group for cancer, will increase by 272% between 2022-2040. The anticipation of an increasing cancer burden poses a challenge to patients, national health services, the economy and broader society.

Population over 65 years¹	173k (2022)	643k (2040)	1 272%
Total cancer incidence ²	4.8k (2020)	15.9k (2040)	1 231%
Total cancer mortality ²	1.9k (2020)	8.2k (2040)	↑ 335%
Probability of premature death from cancer per year in 2030 ³	4.49 % (2020)	2.63 % (SDG target)	Projected to miss 1.86% SDG target by





Policy


While the UAE has a comprehensive and up-to-date NCCP, it has yet to be officially adopted. Implementation of the NCCP is necessary to effectively and systematically combat cancer. The government has expanded screening and early detection efforts with established breast, cervical and colon cancer programmes. However, population coverage among target groups is below WHO targets.4



Early detection programme/guidelines for 4 cancers (breast, cervix, colon, childhood)



of MPOWER measures fully implemented and achieved



Up-to-date NCCP

National screening program for breast cancer

National screening program for cervical cancer

Health System

While health system infrastructure and capacity in the UAE are sufficient to manage today's cancer burden; ongoing efforts are needed to expand prevention interventions and palliative care service locations and reduce reliance on expatriate healthcare workers to maintain access to quality care as the number of cancer patients increases.

Primary prevention & risk factors

26.2% **HPV** vaccination programme coverage

(2018)



Alcohol consumption per capita⁵ (2018)



Prevalence of tobacco use (% of adults)6(2020)



WHO target of girls fully vaccinated with the HPV vaccine by the age of 15



Prevalence of obesity among adults7 (2018)



Measures taken to reduce an unhealthy diet1 (2020)





Awareness campaign for diet and physical activity done every 5 years1 (2020)

Infrastructure9

2,353 Number of

patients who need

radiotherapy per year

100%

Patient / RT unit

Radiotherapy

Availability of palliative care in the public health system³

(Approximately 50% of cancer patients require RT) (2013)

Health workforce



Physicians¹⁰ 2.6 per 1,000 people (2019)

OECD average - 3.6



Nuclear medicine physicians³

31.9 per 10.000 cancer patients (2020)



Nurses¹¹

5.7 per 1,000 people (2019)

OECD average - 8.8



Radiologists³ 1,064 per 10,000 cancer patients (2020)

Innovation & Data

Data on cancer is expected to improve further with the development of the UAE National Cancer Registry (UAE-NCR) and the Riayati platform, a database for all electronic medical records in the country.¹¹ Internet access and smartphone penetration are among the highest globally, providing a good basis for digital health applications. 12,13 Research activity has also gradually increased, with the number of clinical trials rising from 38 in 2012 to 55 in 2022.14 The National Center for Health Research (NCHR) was recently established to support medical innovation and clinical trial activity.¹⁵



100%

Individuals using the Internet¹² (2021)



Research and development (R&D) expenditure (% of GDP)14



Number of mobile phone subscriptions (per 100 people)13 (2021)



Total number of clinical trials for oncology¹⁵ (2022)

Number of clinical trials (1999-2022)¹⁶ (2022)

^{*} MPOWER: Monitor tobacco use and prevention policies, Protect people from tobacco smoke, Offer help to quit tobacco use, Warn about the dangers of tobacco, Enforce bans on tobacco advertising, promotion and sponsorship, and Raise taxes on tobacco. Source: WHO. Cancer Country Profile 2020. UAE³

[^]Total alcohol consumption per capita (liters of pure alcohol, projected estimates, 15+ years of age)

Health Financing

According to the UAE Ministry of Finance, health expenditure was projected to reach \$21 billion by 2021 and \$26 billion by 2025, driven by demographic changes, medical tourism, and the rise in national wealth. This increase in healthcare spending raises the significance of developing a suitable HTA or value assessment system to support resource allocation and evidence-based decision-making. Drug approval timelines for new medicines, at an average of less than six months, are the fastest in the region. There are also efforts to incentivise local manufacturing to reduce exposure to price and supply chain fluctuations and support local R&D. The support local R&

Health Budget²¹

Current health expenditure (CHE) as % of GDP

6% (2020)

13.9% OECD average

Current health expenditure (CHE) per capita US\$2,192 (2020)

\$5,292 OECD average

General government health expenditure as % CHE

66% (2020)

66% OECD average

Private Health Expenditure as % CHE

39% (2020) 34% OECD average

Value Assessment²²

Has a systematic process to support healthcare decision-making?

Is there an existence of a standard methodology

or process guideline?



Are there legislative and / or regulatory requirements to consider HTA results in benefit package decisions?



Barriers to HTA implementation

- Awareness/advocacy of the importance of HTA
- · Mandate from policy authority
- Institutionalisation of HTA
- · Qualified human resources
- Political support

Accessibility



78/100

Progress towards Universal Health Coverage (UHC) - up from 76 in 2005²³ (2021)



Average time to local registration for new medicines¹⁹ (2022)

Economic Burden



\$66 billion

Total macroeconomic cost attributable to cancers between 2020-2050²⁴ (2023)

(Total macroeconomic burden attributable to cancers in 2020–2050 using a discount rate of 3%)

Affordability²¹

Out-of-pocket (OOP) spending as % of current health expenditure (CHE)

11% (2020)

12% OECD average

Out-of-Pocket (OOP) spending per capita in USD

\$246 (2020) \$653 OECD average

Opportunities for Improvement

1 Expand screening programmes

Expanding screening and early detection programmes is one of the most impactful ways to improve cancer survival rates and manage treatment costs. Coverage rates for national screening programmes in the UAE are well below WHO targets, ranging from 1.6% for colon cancer to 7% for cervical cancer among eligible population groups.4 Health authorities should also work with private insurers to expand and promote screening among expatriate residents, who are not covered under national programmes.

2 Explore alternative insurance solutions

While expatriate residents are covered by insurance plans, typically through their employer, these plans are often subject to expiration dates and limitations that do not cover lengthy and costly cancer treatment. Many expatriate patients rely on financial support from NGOs and patient organisations. Alternative solutions to insurance packages that provide financial protection and access to treatment should be explored as the expatriate population increases.

3 Collaborate to develop national cancer capabilities

Several healthcare advancements and Public Private Partnerships (PPPs) in the UAE also support innovation in oncology, including the National Genome Strategy, which has led to personalised precision medicine programmes for oncology, policies and strategies to support the use of AI in healthcare, as well as developments in the delivery of advanced treatments like stem cell therapy, CAR-T cell therapy and bone marrow transplants, providing an opportunity to position the UAE as a leader in innovative and complex care.4

The future of cancer care: health system sustainability in the Middle East and North Africa (MENA):

United Arab Emirates (UAE)

References

- 1. World Bank. Databank, population estimates and projections. United Arab Emirates (Internet). The World Bank. Accessed June 2023. Available from: https://databank.worldbank.org/source/population-estimates-and-projections
- 2. WHO. Cancer: World Health Organization; 2022. Available from: https://www.who.int/newsroom/fact-sheets/detail/cancer
- 3. WHO. Cancer Country Profile 2020. United Arab Emirates. https://cdn.who.int/media/docs/default-source/country-profiles/cancer/are-2020. pdf?sfvrsn=c932b567_2&download=true
- 4. Al-Shamsi HO, Abyad AM, Rafii S. A Proposal for a National Cancer Control Plan for the UAE: 2022-2026. Clin Pract. 2022;12(1):118-132. Published 2022 Feb 17. doi:10.3390/clinpract12010016
- 5. WHO.Total alcohol consumption per capita. Global Health Observatory Data Repository (apps.who.int/ghodata)
- Razzak HA, Harbi A, Ahli S. Tobacco Smoking Prevalence, Health Risk, and Cessation in the UAE. Oman Med J. 2020;35(4):e165. Published 2020 Jul 31. doi:10.5001/omj.2020.107
- 7. World Obesity. Prevalence of adult overweight & obesity (%). Global Obesity Observatory. Available from https://data.worldobesity.org/tables/prevalence-of-adult-overweight-obesity-2/
- 8. MOHAP. National Unified Medical Record (NUMR): UAE Ministry of Health and Prevention; 2023 [Available from: https://riayati.mohap.gov.ae/NUMR.html.
- 9. Provision of radiotherapy in the Eastern Mediterranean Region (EMR): Relation between RT facilities, population and cancer incidence. 2013 International Atomic Energy Agency, DIRAC (Directory of Radiotherapy Centers)
- 10. World Bank. Individuals using the internet (% of population) 2022. Available from: https://data.worldbank.org/indicator/IT.NET.USER.ZS
- 11. World Bank. Physicians (per 1,000 people). Available from https://data.worldbank.org/indicator/SH.MED.PHYS.ZS
- 12. World Bank. Nurses and midwives (per 1,000 people). Available from https://data.worldbank.org/indicator/SH.MED.NUMW.P3
- 13. World Bank. Mobile cellular subscriptions per 100 people. 2021. Available from https://data.worldbank.org/indicator/IT.CEL.SETS.P2
- 14. WHO. Global Observatory on Health Research and Development. Number of clinical trials by year, country, WHO region and income group (1999-2022). Available from https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-clinical-trials-by-year-country-who-region-and-income-group
- 15. UAE Ministry of Health. The National Center for Health Research (NCHR). Available from https://mohap-research.ae/wonca-emr/
- 16. World Bank. Research and development expenditure (% of GDP). Available from https://data.worldbank.org/indicator/GB.XPD.RSDV.GD.ZS
- 17. U.S. National Library of Medicine (ClinicalTrials.gov). Accessed May 2023
- Ahmad, M., Akhras, K., & Saleh, S. (2023). Genuine policy learning is fundamental: The journey of the United Arab Emirates toward the establishment of health technology assessment. International Journal of Technology Assessment in Health Care, 39(1), E3. doi:10.1017/ S0266462322003348
- IQVIA. Assessment of Access-to-Medicine Timelines in Selected Countries in Middle East and Africa. 2021. Available from https://www.iqvia.com/-/media/iqvia/pdfs/mea/white-paper/assessment-of-access-to-medicine-timelines-in-selected-countries-in-middle-east-and-africa.pdf
- 20. IQVIA. Localization of Pharmaceutical Manufacturing in Middle East and North Africa Region. An Evolving Landscape of the Healthcare Ecosystem. 2022. Available from https://www.iqvia.com/-/media/iqvia/pdfs/mea/white-paper/localization-of-pharmaceutical-manufacturing-in-middle-east-and-north-africa-region.pdf
- 21. Global Health Expenditure Database [Internet]. apps.who.int. Available from: https://apps.who.int/nha/database/ViewData/Indicators/en
- 22. WHO. HTA Country Profiles. 2020 2021. https://cdn.who.int/media/docs/default-source/health-economics/hta-country-profiles-2020-21/hta_merged_country_area-profiles_compressed_organized.pdf?sfvrsn=b87e036f_5
- 23. WHO. The Global Health Observatory. UHC service coverage index (3.8.1). 2019
- 24. Chen S, Cao Z, Prettner K, et al. Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. JAMA Oncol. 2023;9(4):465-472. doi:10.1001/jamaoncol.2022.7826